Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.35 |
| ▸ | AKT1 | P31749 | 8/20 | 0.35 |
| ▸ | MTOR | P42345 | 5/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29973654 | 1.00 | PIK3CA (0.35) | PIK3CAAKT1MTORRIPK1PIK3C3 | |
| SCHEMBL25520210 | 0.83 | RAD51 (0.35) | — | |
| SCHEMBL29973648 | 0.83 | RAD51 (0.35) | — | |
| SCHEMBL25519896 | 0.80 | CA12 (0.34) | — | |
| SCHEMBL29973748 | 0.80 | CA12 (0.34) | — | |
| SCHEMBL29973612 | 0.79 | CA1 (0.43) | PIK3CAAKT1MTORRIPK1CXCR2 | |
| SCHEMBL25520194 | 0.79 | CA1 (0.43) | PIK3CAAKT1MTORRIPK1CXCR2 | |
| SCHEMBL28913228 | 0.74 | TSHR (0.33) | — | |
| SCHEMBL25519976 | 0.70 | HTR2A (0.35) | — | |
| SCHEMBL29191944 | 0.69 | NAMPT (0.41) | PIK3CAAKT1MTORPIK3C3NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| CN-115315423-A | Substituted aryl compounds | 先声药业有限公司 | 2022-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | PIK3CA 1288/4885AKT1 691/4885MTOR 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.